Key stats
About F/M Emerald Life Sciences Innovation ETF
Home page
Inception date
Oct 30, 2024
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
F/m Investments LLC
Distributor
Quasar Distributors LLC
ISIN
US74933W2219
LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.83%
Health Technology90.11%
Health Services8.69%
Bonds, Cash & Other1.17%
ETF1.19%
Cash−0.03%
Stock breakdown by region
North America90.16%
Europe6.63%
Asia3.21%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
LFSC invests in stocks. The fund's major sectors are Health Technology, with 90.14% stocks, and Health Services, with 8.69% of the basket. The assets are mostly located in the North America region.
LFSC top holdings are Travere Therapeutics, Inc. and LivaNova Plc, occupying 7.14% and 6.28% of the portfolio correspondingly.
LFSC assets under management is 68.26 M USD. It's risen 7.80% over the last month.
LFSC fund flows account for 8.36 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, LFSC doesn't pay dividends to its holders.
LFSC shares are issued by 1251 Capital Group, Inc. under the brand F/m. The ETF was launched on Oct 30, 2024, and its management style is Active.
LFSC expense ratio is 0.54% meaning you'd have to pay 0.54% of your investment to help manage the fund.
LFSC follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
LFSC invests in stocks.
LFSC price has risen by 5.92% over the last month, and its yearly performance shows a 17.19% increase. See more dynamics on LFSC price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 6.00% over the last month, showed a 18.40% increase in three-month performance and has increased by 25.44% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 6.00% over the last month, showed a 18.40% increase in three-month performance and has increased by 25.44% in a year.
LFSC trades at a premium (0.04%) meaning the ETF is trading at a higher price than the calculated NAV.